Timber Pharmaceuticals, Inc.

Leo Pharma’s turnaround plan has taken root and the company is now in a growth phase on the back of launches like Adbry/Adtralza (tralokinumab) for atopic dermatitis and Anzupgo (delgocitinib) for chr

LEO Pharma A/S is not saying for certain that it has closed the door on its ointment formulation of isotretinoin, but said on 21 August the failure of TMB-001 to hit the primary endpoint in a Phase I

LEO Pharma is poised to gain a first approval for Anzupgo, a new topical treatment for moderate to severe chronic hand eczema (CHE) that is set to become a major earner for the Denmark-headquartered

With its drawn-out acquisition of Timber Pharmaceuticals, Inc. finally signed off, LEO Pharma A/S can now turn its attention to other potential deals that will cement its place as a leading player